The introduction of TissuePatchThoracic has had a positive impact on Tissuemed’s other products. The company has made the decision to phase in all of the improvements demonstrated in TissuePatchThoracic across the other product lines. This means that TissuePatch3 and TissuePatchDural will benefit from seeing non refrigerated storage conditions, improved strength and handling and a flatter, less curl-prone product.
Tissuemed CEO Nick Woods comments: “It’s great news for our other products that these minor changes to our manufacturing process have worked so well, but equally important to realise that the changes do not mean existing inventory is not perfectly functional. We will not be offering to change distributor inventory to new stock, nor are we able to say that only new stock will be shipped with immediate effect. Fundamentally the product stays the same, with exactly the same multilaminate structure of the same chemical components… nevertheless the minor change to our casting process has benefited the product, and we’re excited about what surgeons will tell us about this improvement.”